【文献精选——文献精读】Programmed cell death 1 ligand 1 signals in cancer cells(癌细胞中的程序性细胞死亡1配体1信号) 表面表达的PDL1信号传递到免疫细胞PD1以抑制抗肿瘤免疫的范例有助于开发有效和革命性的免疫疗法,使用抗体阻断这些细胞外部相互作用。最近发现的...
1:Peripheral and tumorimmune correlates in patients with advanced melanoma treated with nivolumab(anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination withipilimumab. J Transl Med 2014;12:O8. 2:PD-L1 Expression asa Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015Apr...
2017年7月13日在线版)——《CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases》。北挪威大学附属医院肿瘤科Erna Elise Paulsen等进行这项研究入组了536例原发的Ⅰ~ⅢA期NSCLC患者手术切除的组织样本,...
In addition, the expression of RORgammat and IL-17 decreased, whereas the expression of Foxp3 and TGF-beta1 increased.Our study demonstrated that gastric cancer resection altered the balance of Th17/Treg cells and increased PD-1/PD-L1 expression 胃癌切除前后CD4+PD-1+T细胞占PBMC的比例:6.34%-...
2022年1月14日,来自美国德克萨斯大学圣安东尼奥分校医学系的Tyler J. Curiel教授课题组在Nat RevCancer(IF: 60.7)杂志上发表题为“Programmed cell death 1 ligand 1 signals in cancer cells”的综述[1]。本文简要讨论了肿瘤细胞固有PD1信号和非肿瘤细胞固有PDL...
1. Combinations take center stage in PD/PDL1 inhibitor clinical trials.2. Combination therapy strategies for improving PD-1 blockadeefficacy: a new era in cancer immunotherapy.3. Landscape of combination therapy trials in breast cancer brainMetastasis.4. Combination immunotherapy: a road map.5. Com...
以下参考文献是使用该技术将特定蛋白质靶向肿瘤组织的实例(senter等,bioconjugatechem.,2:447-451,(1991);bagshawe,k.d.,br.j.cancer,60:275-281,(1989);bagshawe,等,br.j.cancer,58:700-703,(1988);senter等,bioconjugatechem.,4:3-9,(1993);battelli等,cancerimmunol.immunother.,35:421-425,(1992);...
[3] Keir ME, Butte MJ, Freeman GJ,Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol.2008;26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331. PMID: 18173375. [4] Pardoll DM. The blockade ofimmune checkpoints in cancer immunotherapy. Nat Rev Cancer. ...
1. Nivolumab plus Ipilimumab versusSunitinib in Advanced Renal-Cell Carcinoma 2. Combination nivolumab and ipilimumab ornivolumab alone in melanoma brain metastases: a multicentre randomised phase 2study 3. Durvalumab as third-line or latertreatment for advanced non-small-cell lung cancer (ATLANTIC): ...